)
)
Mereo Biopharma Investor Relations Material
Latest events
Study Update
Mereo Biopharma
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Mereo Biopharma Group
Access all reports
Mereo Biopharma Group plc is a biopharmaceutical company that focuses on the development and commercialization of therapies for rare diseases and oncology. The company has a diverse portfolio of product candidates in various stages of clinical development, including treatments for conditions such as osteogenesis imperfecta, Alpha-1 anti-trypsin deficiency, and different types of cancer. Among its leading candidates are etigilimab, an antibody designed for tumor treatment, and alvelestat, intended for Alpha-1 anti-trypsin deficiency. Founded in 2015, Mereo Biopharma Group plc is headquartered in London, United Kingdom, and its shares are listed on the NASDAQ.
Latest articles
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
)
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
MREO
Country
🇺🇸 United States